TY - JOUR
T1 - Research design considerations for randomized controlled trials of spinal cord stimulation for pain
T2 - Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials/Institute of Neuromodulation/International Neuromodulation Society recommendations
AU - Katz, Nathaniel
AU - Dworkin, Robert H.
AU - North, Richard
AU - Thomson, Simon
AU - Eldabe, Sam
AU - Hayek, Salim M.
AU - Kopell, Brian H.
AU - Markman, John
AU - Rezai, Ali
AU - Taylor, Rod S.
AU - Turk, Dennis C.
AU - Buchser, Eric
AU - Fields, Howard
AU - Fiore, Gregory
AU - Ferguson, McKenzie
AU - Gewandter, Jennifer
AU - Hilker, Chris
AU - Jain, Roshini
AU - Leitner, Angela
AU - Loeser, John
AU - McNicol, Ewan
AU - Nurmikko, Turo
AU - Shipley, Jane
AU - Singh, Rahul
AU - Trescot, Andrea
AU - Van Dongen, Robert
AU - Venkatesan, Lalit
N1 - Publisher Copyright:
© 2021 Lippincott Williams and Wilkins. All rights reserved.
PY - 2021/7/1
Y1 - 2021/7/1
N2 - Spinal cord stimulation (SCS) is an interventional nonpharmacologic treatment used for chronic pain and other indications. Methods for evaluating the safety and efficacy of SCS have evolved from uncontrolled and retrospective studies to prospective randomized controlled trials (RCTs). Although randomization overcomes certain types of bias, additional challenges to the validity of RCTs of SCS include blinding, choice of control groups, nonspecific effects of treatment variables (eg, paresthesia, device programming and recharging, psychological support, and rehabilitative techniques), and safety considerations. To address these challenges, 3 professional societies (Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials, Institute of Neuromodulation, and International Neuromodulation Society) convened a meeting to develop consensus recommendations on the design, conduct, analysis, and interpretation of RCTs of SCS for chronic pain. This article summarizes the results of this meeting. Highlights of our recommendations include disclosing all funding source and potential conflicts; incorporating mechanistic objectives when possible; avoiding noninferiority designs without internal demonstration of assay sensitivity; achieving and documenting double-blinding whenever possible; documenting investigator and site experience; keeping all information provided to patients balanced with respect to expectation of benefit; disclosing all information provided to patients, including verbal scripts; using placebo/sham controls when possible; capturing a complete set of outcome assessments; accounting for ancillary pharmacologic and nonpharmacologic treatments in a clear manner; providing a complete description of intended and actual programming interactions; making a prospective ascertainment of SCS-specific safety outcomes; training patients and researchers on appropriate expectations, outcome assessments, and other key aspects of study performance; and providing transparent and complete reporting of results according to applicable reporting guidelines.
AB - Spinal cord stimulation (SCS) is an interventional nonpharmacologic treatment used for chronic pain and other indications. Methods for evaluating the safety and efficacy of SCS have evolved from uncontrolled and retrospective studies to prospective randomized controlled trials (RCTs). Although randomization overcomes certain types of bias, additional challenges to the validity of RCTs of SCS include blinding, choice of control groups, nonspecific effects of treatment variables (eg, paresthesia, device programming and recharging, psychological support, and rehabilitative techniques), and safety considerations. To address these challenges, 3 professional societies (Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials, Institute of Neuromodulation, and International Neuromodulation Society) convened a meeting to develop consensus recommendations on the design, conduct, analysis, and interpretation of RCTs of SCS for chronic pain. This article summarizes the results of this meeting. Highlights of our recommendations include disclosing all funding source and potential conflicts; incorporating mechanistic objectives when possible; avoiding noninferiority designs without internal demonstration of assay sensitivity; achieving and documenting double-blinding whenever possible; documenting investigator and site experience; keeping all information provided to patients balanced with respect to expectation of benefit; disclosing all information provided to patients, including verbal scripts; using placebo/sham controls when possible; capturing a complete set of outcome assessments; accounting for ancillary pharmacologic and nonpharmacologic treatments in a clear manner; providing a complete description of intended and actual programming interactions; making a prospective ascertainment of SCS-specific safety outcomes; training patients and researchers on appropriate expectations, outcome assessments, and other key aspects of study performance; and providing transparent and complete reporting of results according to applicable reporting guidelines.
KW - Clinical research methods
KW - Clinical trials
KW - Medical devices
KW - Randomized controlled trials
KW - Spinal cord stimulation
UR - http://www.scopus.com/inward/record.url?scp=85108386861&partnerID=8YFLogxK
U2 - 10.1097/j.pain.0000000000002204
DO - 10.1097/j.pain.0000000000002204
M3 - Review article
C2 - 33470748
AN - SCOPUS:85108386861
SN - 0304-3959
VL - 162
SP - 1935
EP - 1956
JO - Pain
JF - Pain
IS - 7
ER -